Meeting
2018 Genitourinary Cancers Symposium
Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi).
Authors
Jacob A Gordon
Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
Jacob A Gordon , Bernhard J. Eigl , Jennifer A. Locke , Gregory Russell Pond , Cyrus Chehroudi , Daniel Khalaf , Kim N. Chi , Michael E. Cox
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 277)
DOI
10.1200/JCO.2018.36.6_suppl.277
Abstract #
277
Poster Bd #
N9
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan
Poster
2018 Genitourinary Cancers Symposium
Abiraterone acetate in metastatic castration-resistant prostate cancer post-docetaxel: A “real-life” retrospective analysis of outcomes in a Brazilian public health institution.
First Author: Thais Caroline Menegasso Flores
Poster
2016 Genitourinary Cancers Symposium
Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in chemotherapy-naive patients (CN-pts) with metastatic castration resistant prostate cancer (mCRPC).
First Author: Avivit Peer
Poster
2016 Genitourinary Cancers Symposium
Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI).
First Author: Tilman Todenhöfer